Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.6852W HIGH $3.68
Volume
23.22 K
Value Traded
43.63 K
Short % Float
0.07%
+2.71%Week
+18.9%1 Month
-8.26%3 Month
-5.51%6 Month
-71.75%5 Year
-71.75%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
11.18 M
EPS (TTM)
-0.26
P/E Ratio
-
Ent. Value
12.36 M
Total Shares
11.83 M
Float Shares
5.20 M
Insiders
56.10%
Institutions
0.10%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
GDTC Catalyst Timeline
Dated clinical, regulatory and corporate events for CytoMed Therapeutics Limited
Catalyst Timeline
Dated clinical, regulatory & corporate events for CytoMed Therapeutics Limited
60Total events
3Upcoming
13Tier-1 (high impact)
2023 to 2026Coverage
Upcoming catalysts 2
TBD
T2IND Submission
Subscribe to view catalyst details
TBD
T2Equity Offering
Subscribe to view catalyst details
Event history 50
◆Trial InitiationCTM-GDTTrial
Multi-site first-in-human Phase I trial of CTM-GDT planned with Universiti Malaya
no-option cancer patientssource ↗
●IND SubmissionCTM-GDTIND
IND submission to Malaysian authorities for CTM-GDT
no-option cancer patientssource ↗
▲Trial InitiationTrial
First-in-human clinical trial ongoing at National University Hospital, Singapore
cancerssource ↗
◆Enrollment UpdateCTM-N2DTrial
Six patients dosed in CTM-N2D Phase I trial
advanced colorectal cancer, lymphoma, multiple myeloma, lung cancer, ovarian cancer, hepatocellular carcinomasource ↗
▲Partnership / LicenseCorporate
Memorandum of Understanding with Universiti Malaya for CTM-GDT trial
◆Trial InitiationCTM-GDTTrial
First-in-human Phase I clinical trial of CTM-GDT planned with UMMC
no-option cancer patientssource ↗
◆Trial InitiationCTM-N2DTrial
Ongoing first-in-human Phase I trial of CTM-N2D in Singapore
advanced colorectal cancer, lymphoma, multiple myeloma, lung cancer, ovarian cancer, hepatocellular carcinomasource ↗
▲Partnership / LicenseCorporate
CytoMed secures non-dilutive investment for subsidiary LongevityBank from ICH Capital
▲Patent GrantedIP / Competition
Patent granted by China National Intellectual Property Administration for gamma delta T cell and CAR-T cell technology
cancersource ↗
◆AcquisitionCorporate
CytoMed submits cash bid for potential acquisition of TC BioPharm Limited's assets
▲PublicationCTM-GDTPresentation
Publication of preclinical study on donor-derived Vδ9Vδ2 T cells for AML
acute myeloid leukemiasource ↗
▲PublicationCTM-GDTPresentation
Publication of preclinical study on CTM-GDT for AML
acute myeloid leukemia (AML)source ↗
▲Preclinical PoCCTM-GDTPreclinical
Preclinical study published with MD Anderson showing potential of CTM-GDT for AML
acute myeloid leukemia (AML)source ↗
▲Dose Finding UpdateCTM-N2DTrial
Completion of Dose Level 1
advanced solid tumors or haematological malignanciessource ↗
◆Dose Finding UpdateCTM-N2DTrial
Proceeding to Dose Level 2
advanced solid tumors or haematological malignanciessource ↗
▲First Patient DosedTrial
First patient recruitment anticipated for Phase II IIT in India
various cancer indicationssource ↗
●IND SubmissionIND
Target submission of Phase I clinical trial dossier for umbilical cord-derived stem cells to treat osteoarthritis
osteoarthritissource ↗
●Trial RegisteredTrial
Phase II IIT registered with Clinical Trials Registry - India
various cancer indicationssource ↗
▲Partnership / LicenseCorporate
Business & Research Collaboration Agreement with SunAct Cancer Institute
solid cancerssource ↗
●IND SubmissionIND
Plan to submit U.S. FDA IND application for donor-derived allogeneic gamma delta T cells for leukemia
leukemiasource ↗
▲First Patient DosedCTM-N2DTrial
First patient dosed in first-in-human Phase I trial of CTM-N2D
advanced solid tumours or haematological malignanciessource ↗
●Quarterly UpdateCorporate
Earnings conference call for six months ended June 30, 2024 financial results
▲Trial InitiationTrial
Part 2 (recipient protocol) may now proceed with patient recruitment
advanced cancers resistant to standard therapysource ↗
●Enrollment UpdateTrial
Part 1 (donor protocol) ongoing with recruitment of healthy blood donors
blood and solid tumorssource ↗
▲Partnership / LicenseCorporate
Acquisition of assets and licence of a licenced cord blood bank in Malaysia
▲AcquiredCorporate
CytoMed completed asset acquisition of licensed cord blood bank in Malaysia
▲AcquisitionCorporate
CytoMed completes cash acquisition of cord blood banking licence and assets from Cellsafe International Sdn Bhd
▲Partnership / LicenseCorporate
Research Collaboration with Sengkang General Hospital for UC-MSC cartilage therapy
cartilage diseases and repairsource ↗
▲Patent GrantedIP / Competition
Malaysian patent granted for allogeneic CAR-gamma delta T cell technology
solid and hematological tumorssource ↗
●IND SubmissionIND
Drug master file submitted to FDA in preparation for IND filing
hematological and solid cancerssource ↗
▲Patent GrantedIP / Competition
Chinese patent granted for iPSC-based technology
various cancers including hematological malignancies and solid tumorssource ↗
▲Patent GrantedIP / Competition
Chinese patent granted for CAR-gamma delta T cell technology
cancersource ↗
▲Patent GrantedIP / Competition
US patent granted for CAR-gamma delta T cell technology
cancersource ↗
▼Equity OfferingCorporate
Initial public offering completed, issued 2,412,369 ordinary shares at $4.00 per share
Past FDA Catalysts and PDUFA Decisions
How GDTC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
F16 / 100
Pipeline Score
$1M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 98%
Micro Cap(rank 645 of 658)
Percentile Rank
CytoMed Therapeutics Limited has significant pipeline risk (16/100), with $126M risk-adjusted pipeline value, led by CTM-N2D in Cancer (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CTM-N2D CAR-TNCT05302037 | Cancer | Phase 1 | RECRUITING | 12 | Dec 1, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every GDTC program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Choo Chee KongDirector, 10% Owner | Buy | -100,000 630,324 held | $1.50 | 07/20/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in GDTC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in GDTC for Q2 2026. | ||||
GDTC Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How GDTC ranks across every disease it competes in
Competitive Position is a premium feature
See how GDTC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialGDTC News
GDTCCytoMed Therapeutics Limited 1 Commonwealth Lane #08-22 Singapore 149544 PROXY STATEMENT AND NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To the shareholders of
CytoMed Therapeutics Limited has announced its Annual General Meeting (AGM) scheduled for May 22, 2026, at its office in Singapore. Shareholders are encouraged to vote either by internet or mail, whether or not they attend the meeting. The AGM will address various proposals, including the adoption of financial statements, re-elections of directors, and the appointment of public accounting firms. Shareholders can also participate via a webcast if they are unable to attend in person.
Read more →GDTCCytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress
CytoMed Therapeutics has issued a statement refuting misleading claims about its clinical progress and operations. The company emphasizes its commitment to developing CAR γδ T cell therapies and confirms that its lead program is currently undergoing a first-in-human clinical trial. CytoMed aims to clarify its regulatory standing and operational integrity amidst public misinformation.
Read more →GDTCCytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital
CytoMed Therapeutics has updated shareholders on its progress and plans for 2026, including the development of new therapies and a Phase I clinical trial for gamma delta T cells. The company is also exploring innovative ways to enhance shareholder value and has received government support for its initiatives. Additionally, they are seeking feedback from shareholders on a new scheme related to their therapies.
Read more →GDTCCytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia
CytoMed Therapeutics Limited announced a collaboration with Universiti Malaya Medical Centre to conduct a first-in-human Phase I clinical trial for its allogeneic Gamma Delta T cells. This partnership aims to explore the safety and efficacy of its donor-derived immunotherapy for cancer patients in Malaysia. The initiative represents a step towards providing more affordable and accessible treatment options, particularly for those with limited alternatives. CytoMed's innovative technology may enhance cancer treatment landscapes in Southeast Asia, building on supportive findings from past studies.
Read more →GDTCCytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India
CytoMed Therapeutics has finalized its acquisition of the TCB-002 technology from TC BioPharm Limited, aimed at enhancing its cancer treatment capabilities. The technology, which has received orphan drug designation from the FDA for Acute Myeloid Leukemia, will support CytoMed's development of affordable allogeneic gamma delta T cell immunotherapies. The company is in talks with potential partners to adapt the technology for use in China and India, following recent regulatory changes in China that favor the clinical use of cellular therapies. The financial impact of this acquisition is not expected to be immediate.
Read more →GDTCCytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy
CytoMed Therapeutics has successfully secured a non-dilutive investment of up to $500,000 for its subsidiary, LongevityBank, from ICH Capital. The investment aims to enhance LongevityBank's focus on autologous therapies, leveraging personalized cellular banking services. Alongside this, CytoMed is repositioning its strategies toward the Chinese market, especially to introduce cost-effective cell therapy solutions. Notably, the company plans to offer free access to clinical trials for qualified shareholders, reflecting its commitment to innovative cancer care.
Read more →GDTCCytoMed Therapeutics' Chairman Increases Effective Holdings to 21.95% Singapore, Singapore - (
CytoMed Therapeutics Limited announced that its Executive Chairman, Peter Choo, has increased his holdings to 21.95% following recent share purchases. Choo expressed confidence in the company's proprietary technologies aimed at affordable cancer treatments amid rising investor interest in biotherapeutics, particularly in Asia. The company has highlighted opportunities due to the region's growing healthcare ecosystem and favorable regulatory environment. However, investors are cautioned to proceed carefully as updates on further purchases and potential risks are forthcoming.
Read more →GDTC▲ +16.6%on this news
makes cash bid for potential acquisition of TC BioPharm Limited's relevant assets
CytoMed Therapeutics Limited has announced a cash bid for the potential acquisition of relevant assets from TC BioPharm Limited, which is currently under administration. This Proposed Acquisition aims to strengthen CytoMed's expertise in donor-derived cell therapies for cancer treatment, potentially speeding up its commercialization process. CytoMed's Chairman, Peter Choo, highlighted advancements in using gamma delta T cells and the company’s strategic focus on making therapies more accessible in Southeast Asia. The company is also funding the acquisition through its internal resources, with more details expected to follow.
Read more →GDTCCytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic T Cells in Acute Myeloid Leukemia
CytoMed Therapeutics has published a preclinical study in collaboration with MD Anderson Cancer Center, highlighting the potential of their allogeneic T cell therapy in treating acute myeloid leukemia (AML). The findings support further clinical research into this therapy, suggesting a promising approach to treatment. The publication follows a previous research agreement established in May 2023, with plans to advance their T cell-based products into clinical trials in Southeast Asia. This collaboration aims to provide novel immunotherapy options for patients with limited alternatives.
Read more →GDTCCYTOMED THERAPEUTICS LIMITED AND SUBSIDIARIES UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS INDEX Page Unaudited Interim Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Loss fo
Cytomed Therapeutics Limited reported its unaudited interim condensed consolidated financial statements for the six months ending June 30 for the years 2024 and 2025. The company experienced significant financial strain, with a loss before income tax of S$2,245,828 in 2025, marking a deepening financial crisis. Comprehensive losses also rose sharply, totaling S$2,269,263 over the same period, alongside accumulated losses totaling S$17,091,895. These losses reflect both operating expenses that outpaced revenue generation and increased financial liabilities.
Read more →GDTCon recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition
CytoMed Therapeutics has announced its expansion into auto-immune disease therapies following the acquisition of a licensed cord blood bank in Malaysia. The company plans to leverage its resources to create new cord blood-derived therapeutics, particularly focusing on natural killer (NK) cells. This strategic move is expected to establish new revenue streams while also enhancing its overall clinical offerings. CytoMed's management has indicated a commitment to invest significantly in new equipment to support this initiative.
Read more →GDTCCytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program
CytoMed Therapeutics Limited has announced an At-the-Market (ATM) offering program through which it can raise up to $4.3 million. This financing initiative is aimed at supporting general corporate purposes, including potential acquisitions and strategic investments. The Company has shown positive engagement with approximately 2,500 new customer sign-ups for its cord blood bank since its acquisition in August 2024, contributing to revenue growth in 2025. The timing and amount of sales will depend on market conditions and the Company’s capital needs.
Read more →GDTCUpdate On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies SI
CytoMed Therapeutics has announced the successful completion of dose level 1 of its Phase I ANGELICA Trial, which is investigating a new treatment for advanced solid tumors and hematological malignancies. The trial focuses on allogeneic CAR gamma delta T cells, specifically targeting NKG2DL, providing a novel approach to cancer therapy. Following the completion of the first dose level, the company is set to advance to dose level 2, marking a significant milestone in its clinical development efforts. This trial could offer new treatment avenues for patients with challenging cancers.
Read more →GDTC▲ +5.7%on this news
CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results
CytoMed Therapeutics reported its financial results for the year ended December 31, 2024, showing a significant reduction in net losses and sustained operational growth. The company is actively pursuing clinical developments, including its first CAR T trial involving gamma delta T cells, and plans to expand its technology platforms in the ASEAN region. A cord blood bank acquisition aims to support new therapeutic developments in autoimmune conditions and cancers. Nevertheless, they must remain vigilant amid global economic uncertainties while capitalizing on the positive momentum in their clinical programs.
Read more →GDTCCytoMed Therapeutics signs Business & Research Collaboration Agreement with India's SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in India
CytoMed Therapeutics has entered into a Business & Research Collaboration Agreement with SunAct Cancer Institute to advance the use of allogeneic gamma delta T Cells for the treatment of solid cancers. The collaboration will facilitate an accelerated clinical trial in India, focusing on safety, efficacy, and optimal dosing. This partnership aims to provide accessible cancer therapies while contributing to global cancer treatment data. CytoMed would be responsible for the manufacturing of the T cells, while SunAct's expertise will aid in conducting the trials.
Read more →GDTC▲ +10%on this news
Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haema
CytoMed Therapeutics has announced that the first patient has been dosed in its Phase I clinical trial, known as the ANGELICA Trial, evaluating allogeneic CAR-Gamma Delta T Cell therapy for advanced solid tumors and hematological malignancies. The trial aims to examine the safety and efficacy of this novel therapeutic approach, which leverages donor blood-derived cells. This milestone is significant for the company as it expands its clinical capabilities in the immunotherapy space. CytoMed, a spin-off from Singapore's A*STAR, focuses on innovative cell-based treatments for various cancers.
Read more →GDTC▲ +10%on this news
CytoMed Therapeutics' first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the N
CytoMed Therapeutics Limited has announced the initiation of its first-in-human Phase I ANGELICA clinical trial, which focuses on utilizing its patented donor allogeneic chimeric antigen receptor T cell therapy against various blood and solid tumors. Supported by co-funding from the National Medical Research Council (NMRC) of Singapore, the trial aims to recruit patients suffering from relapsed cancer. This innovative approach involves using gamma delta T cells, which can be modified from healthy donors, potentially allowing for more accessible cancer treatments. Additionally, CytoMed has recently acquired a cord blood bank to enhance its research and development capabilities.
Read more →GDTCCytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed's strategy to cord blood-derived biologics through subsidiary, LongevityBank SINGAPORE
CytoMed Therapeutics has acquired the cord blood banking license and assets from Cellsafe International through its subsidiary, IPSC Depository Sdn Bhd. This strategic move, which includes over 12,000 cord blood units and cryopreservation equipment, aims to bolster the company's focus on cord blood-derived biologics. The acquisition is expected to enhance CytoMed's capabilities in cell therapy, particularly in targeting regenerative medicine and combating various diseases. The company plans to develop this subsidiary further, with future plans for it to be spun off.
Read more →About CytoMed Therapeutics Limited
BIOPHARMAWATCH ELITE PLUS
Trade the next GDTC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime